Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) to Announce -$0.12 Earnings Per Share

Wall Street brokerages forecast that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report ($0.12) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Celldex Therapeutics’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.17). Celldex Therapeutics reported earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The business is expected to announce its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.15) per share for the current year, with EPS estimates ranging from ($1.26) to ($1.06). For the next financial year, analysts expect that the company will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.72) to ($0.26). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. Celldex Therapeutics had a negative return on equity of 47.40% and a negative net margin of 1,159.26%. The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $2.70 million.

Several research firms have recently weighed in on CLDX. HC Wainwright set a $2.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Cowen reissued a “hold” rating on shares of Celldex Therapeutics in a research report on Thursday, August 9th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Celldex Therapeutics in a research note on Friday, August 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.75.

Shares of CLDX stock traded down $0.01 during mid-day trading on Friday, hitting $0.41. The company’s stock had a trading volume of 1,929,000 shares, compared to its average volume of 2,235,763. Celldex Therapeutics has a 52 week low of $0.40 and a 52 week high of $3.09. The firm has a market cap of $71.80 million, a PE ratio of -0.51 and a beta of 2.29.

Several institutional investors and hedge funds have recently modified their holdings of CLDX. BlackRock Inc. grew its stake in shares of Celldex Therapeutics by 1.7% in the 1st quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after buying an additional 166,780 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Celldex Therapeutics by 3,392.4% in the 1st quarter. JPMorgan Chase & Co. now owns 991,184 shares of the biopharmaceutical company’s stock valued at $2,309,000 after buying an additional 962,803 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Celldex Therapeutics by 74.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after buying an additional 1,783,765 shares during the period. Acadian Asset Management LLC grew its stake in shares of Celldex Therapeutics by 378.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after buying an additional 915,863 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Celldex Therapeutics by 27.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 195,147 shares during the period. Institutional investors own 33.48% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Featured Article: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply